Moving towards supraspinal TRPV1 receptors for chronic pain relief

Molecular Pain

Volumn 6, Issue , 2010, Pages

  Palazzo, Enza ^a   Luongo, Livio ^a   de Novellis, Vito ^a   Berrino, Liberato ^a   Rossi, Francesco ^a   Maione, Sabatino ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

(5 TERT BUTYL 2,3 DIHYDRO 1H INDEN 1 YL) 3 (1H INDAZOL 4 YL)UREA; 1 (5 ISOQUINOLINYL) 3 [4 (TRIFLUOROMETHYL)BENZYL]UREA; 1 [3 (TRIFLUOROMETHYL)PYRIDIN 2 YL] N [4 (TRIFLUOROMETHYLSULFONYL)PHENYL] 1,2,3,6 TETRAHYDROPYRIDINE 4 CARBOXAMIDE; 7 PHENYL 1 [5 (2 PYRIDINYL) 2 OXAZOLYL] 1 HEPTANONE; A 784168; A 795614; AMG 8562; CANNABIDIOL; CANNABINOID RECEPTOR; CAPSAICIN; CAPSAZEPINE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; N (1,4 BENZODIOXAN 6 YL) 3 (4 TERT BUTYLPHENYL)ACRYLAMIDE; N (2 HYDROXY 2,3 DIHYDRO 1H INDEN 4 YL) 3 [2 (PIPERIDIN 1 YL) 4 (TRIFLUOROMETHYL)PHENYL]ACRYLAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; N (4 TERT BUTYLPHENYL) 4 (3 CHLORO 2 PYRIDINYL) 1 PIPERAZINECARBOXAMIDE; N 1H INDAZOL YL N' [5 PIPERIDIN 1 YL 2,3 DIHYDRO 1H INDEN 1 YL]UREA; N [4 [6 [4 (TRIFLUOROMETHYL)PHENYL] 4 PYRIMIDINYLOXY]BENZOTHIAZOL 2 YL]ACETAMIDE; N ARACHIDONOYLSEROTONIN; NERVE GROWTH FACTOR; PLACEBO; RESINIFERATOXIN; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 ANTAGONIST; VANILLOID RECEPTOR; VANILLOID RECEPTOR SUBTYPE 1;

ANALGESIC ACTIVITY; ANTINOCICEPTION; APPLICATION SITE DISCOMFORT; APPLICATION SITE IRRITATION; APPLICATION SITE PAIN; ASTROCYTE; BODY TEMPERATURE; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; CLINICAL TRIAL; DRUG EFFICACY; DRUG PENETRATION; DRUG TARGETING; HUMAN; HYPERALGESIA; HYPERTHERMIA; INFLAMMATION; MICROGLIA; NERVE CELL PLASTICITY; NEUROPATHIC PAIN; NEUROPATHOLOGY; NONHUMAN; PAIN; PERIPHERAL NERVOUS SYSTEM; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; TISSUE DISTRIBUTION; TOOTH PAIN; ANIMAL; CHRONIC DISEASE; DRUG ANTAGONISM; METABOLISM; NOCICEPTIVE RECEPTOR; PATHOPHYSIOLOGY; SPINAL CORD;

ANIMALS; CHRONIC DISEASE; NEURONAL PLASTICITY; NOCICEPTORS; PAIN; SPINAL CORD; TRPV CATION CHANNELS;

EID: 77957688293     PISSN: 17448069     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-8069-6-66     Document Type: Review

References (135)

1. Montell C, Rubin GM. Molecular characterization of the Drosophila trp locus: a putative integral membrane protein required for phototransduction. Neuron 1989, 2:1313-1323. 10.1016/0896-6273(89)90069-X, 2516726.
2. Ramsey IS, Delling M, Clapham DE. An introduction to TRP channels. Annu Rev Physiol 2006, 68:619-647. 10.1146/annurev.physiol.68.040204.100431, 16460286.
3. Nilius B, Voets T. TRP channels: a TR(I)P through a world of multifunctional cation channels. Pflugers Arch 2005, 451:1-10. 10.1007/s00424-005-1462-y, 16012814.
4. Pedersen SF, Owsianik G, Nilius B. TRP channels: an overview. Cell Calcium 2005, 38:233-252. 10.1016/j.ceca.2005.06.028, 16098585.
5. Montell C, Birnbaumer L, Flockerzi V. The TRP channels, a remarkably functional family. Cell 2002, 108:595-598. 10.1016/S0092-8674(02)00670-0, 11893331.
6. Moran MM, Xu H, Clapham DE. TRP ion channels in the nervous system. Curr Opin Neurobiol 2004, 14:362-369. 10.1016/j.conb.2004.05.003, 15194117.
7. Patapoutian A, Tate S, Woolf CJ. Transient receptor potential channels: targeting pain at the source. Nat Rev Drug Dis 2009, 8:55-68.
8. Montell C, Birnbaumer L, Flockerzi V, Bindels RJ, Bruford EA, Caterina MJ, Clapham DE, Harteneck C, Heller S, Julius D, Kojima I, Mori Y, Penner R, Prawitt D, Scharenberg AM, Schultz G, Shimizu N, Zhu MX. A unified nomenclature for the superfamily of TRP cation channels. Mol Cell 2002, 9:229-231. 10.1016/S1097-2765(02)00448-3, 11864597.
9. Clapham DE, Runnels LW, Strubing C. The TRP ion channel family. Nat Rev Neurosci 2001, 2:387-396. 10.1038/35077544, 11389472.
10. Kedei N, Szabo T, Lile JD, Treanor JJ, Olah Z, Iadarola MJ, Blumberg PM. Analysis of the native quaternary structure of vanilloid receptor 1. J Biol Chem 2001, 276:28613-28619. 10.1074/jbc.M103272200, 11358970.
11. Tominaga M, Tominaga T. Structure and function of TRPV1. Pflugers Arch 2005, 451:143-150. 10.1007/s00424-005-1457-8, 15971082.
12. Ferrer-Montiel A, Garcia-Martinez C, Morenilla-Palao C, Garcia-Sanz N, Fernandez-Carvajal A, Fernandez-Ballester G, Planells-Cases R. Molecular architecture of the vanilloid receptor. Insights for drug design. Eur J Biochem 2004, 271:1820-1826. 10.1111/j.1432-1033.2004.04083.x, 15128292.
13. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389:816-824. 10.1038/39807, 9349813.
14. Szallasi A, Blumberg PM. Resiniferatoxin, a phorbol-related diterpene, acts as an ultrapotent analog of capsaicin, the irritant constituent in red pepper. Neuroscience 1989, 30:515-20. 10.1016/0306-4522(89)90269-8, 2747924.
15. Caterina MJ, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci 2001, 24:487-517. 10.1146/annurev.neuro.24.1.487, 11283319.
16. Gunthorpe MJ, Harries MH, Prinjha RK, Davis JB, Randall A. Voltage- and time-dependent properties of the recombinant rat vanilloid receptor (rVR1). J Physiol 2000, 3:747-59.
17. Piper AS, Yeats JC, Bevan S, Docherty RJ. A study of the voltage dependence of capsaicin-activated membrane currents in rat sensory neurones before and after acute desensitization. J Physiol 1999, 518:721-33. 10.1111/j.1469-7793.1999.0721p.x, 2269463, 10420009.
18. Hwang SW, Cho H, Kwak J, Lee SY, Kang CJ, Jung J, Cho S, Min KH, Suh YG, Kim D, Oh U. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci USA 2000, 97:6155-60. 10.1073/pnas.97.11.6155, 18574, 10823958.
19. Price TJ, Patwardhan A, Akopian AN, Hargreaves KM, Flores CM. Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. Br J Pharmacol 2004, 141:1118-30. 10.1038/sj.bjp.0705711, 1574881,1574881, 15006899.
20. Suh YG, Oh U. Activation and activators of TRPV1 and their pharmaceutical implication. Curr Pharm Des 2005, 11:2687-98. 10.2174/1381612054546789, 16101449.
21. Liu L, Simon SA. Similarities and differences in the currents activated by capsaicin, piperine, and zingerone in rat trigeminal ganglion cells. J Neurophysiol 1996, 76:1858-1869.
22. McNamara FN, Randall A, Gunthorpe MJ. Effects of piperine, the pungent component of black pepper, at the human vanilloid receptor (TRPV1). Br J Pharmacol 2005, 144:781-790. 10.1038/sj.bjp.0706040, 1576058, 15685214.
23. Dedov VN, Tran VH, Duke CC, Connor M, Christie MJ, Mandadi S, Roufogalis BD. Gingerols: a novel class of vanilloid receptor (VR1) agonists. Br J Pharmacol 2002, 137:793-798. 10.1038/sj.bjp.0704925, 1573550, 12411409.
24. Witte DG, Cassar SC, Masters JN, Esbenshade T, Hancock AA. Use of a fluorescent imaging plate reader--based calcium assay to assess pharmacological differences between the human and rat vanilloid receptor. J Biomol Screen 2002, 7:466-475. 10.1177/108705702237679, 14599363.
25. Iwasaki Y, Morita A, Iwasawa T, Kobata K, Sekiwa Y, Morimitsu Y, Kubota K, Watanabe T. : A nonpungent component of steamed ginger--[10]-shogaol--increases adrenaline secretion via the activation of TRPV1. Nutr Neurosci 2006, 9:169-178. 10.1080/10284150600955164, 17176640.
26. Yang BH, Piao ZG, Kim YB, Lee CH, Lee JK, Park K, Kim JS, Oh SB. Activation of vanilloid receptor 1 (VR1) by eugenol. J Dent Res 2003, 82:781-785. 10.1177/154405910308201004, 14514756.
27. Macpherson LJ, Geierstanger BH, Viswanath V, Bandell M, Eid SR, Hwang S, Patapoutian A. The pungency of garlic: activation of TRPA1 and TRPV1 in response to allicin. Curr Biol 2005, 15:929-934. 10.1016/j.cub.2005.04.018, 15916949.
28. Xu H, Blair NT, Clapham DE. Camphor activates and strongly desensitizes the transient receptor potential vanilloid subtype 1 channel in a vanilloid-independent mechanism. J Neurosci 2005, 25:8924-8937. 10.1523/JNEUROSCI.2574-05.2005, 16192383.
29. Holzer P. Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience 1988, 24:739-768. 10.1016/0306-4522(88)90064-4, 3288903.
30. Oseguera AJ, Islas LD, Garcia-Villegas R, Rosenbaum T. On the mechanism of TBA block of the TRPV1 channel. Biophys J 2007, 92:3901-3914. 10.1529/biophysj.106.102400, 1868982, 17369424.
31. Ryu S, Liu B, Qin F. Low pH potentiates both capsaicin binding and channel gating of VR1 receptors. J Gen Physiol 2003, 122:45-61. 10.1085/jgp.200308847, 2234467, 12835470.
32. Reeh PW, Kress M. Molecular physiology of proton transduction in nociceptors. Curr Opin Pharmacol 2001, 1:45-51. 10.1016/S1471-4892(01)00014-5, 11712534.
33. Szallasi A, Blumberg PM. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 1999, 51:159-212.
34. Szallasi A, Nilsson S, Farkas-Szallasi T, Blumberg PM, Hokfelt T, Lundberg JM. Vanilloid (capsaicin) receptors in the rat: distribution in the brain, regional differences in the spinal cord, axonal transport to the periphery, and depletion by systemic vanilloid treatment. Brain Res 1995, 703:175-183. 10.1016/0006-8993(95)01094-7, 8719630.
35. Szallasi A, Blumberg PM. Characterization of vanilloid receptors in the dorsal horn of pig spinal cord. Brain Res 1991, 547:335-338. 10.1016/0006-8993(91)90982-2, 1884211.
36. Szolcsanyi J, Szallasi A, Szallasi Z, Joo F, Blumberg PM. Resiniferatoxin. An ultrapotent neurotoxin of capsaicin-sensitive primary afferent neurons. Ann N Y Acad Sci 1991, 632:473-475. 10.1111/j.1749-6632.1991.tb33161.x, 1952635.
37. Szolcsanyi J, Szallasi A, Szallasi Z, Joo F, Blumberg PM. Resiniferatoxin: an ultrapotent selective modulator of capsaicin-sensitive primary afferent neurons. J Pharmacol Exp Ther 1990, 255:923-928.
38. Fischer MJ, Reeh PW, Sauer SK. Proton-induced calcitonin gene-related peptide release from rat sciatic nerve axons, in vitro, involving TRPV1. Eur J Neurosci 2003, 18:803-810. 10.1046/j.1460-9568.2003.02811.x, 12925006.
39. Bernardini N, Neuhuber W, Reeh PW, Sauer SK. Morphological evidence for functional capsaicin receptor expression and calcitonin gene-related peptide exocytosis in isolated peripheral nerve axons of the mouse. Neuroscience 2004, 126:585-590. 10.1016/j.neuroscience.2004.03.017, 15183508.
40. Price TJ, Flores CM. Critical evaluation of the colocalization between calcitonin gene-related peptide, substance P, transient receptor potential vanilloid subfamily type 1 immunoreactivities, and isolectin B4 binding in primary afferent neurons of the rat and mouse. J Pain 2007, 8:263-272. 10.1016/j.jpain.2006.09.005, 1899162, 17113352.
41. Price TJ, Louria MD, Candelario-Soto D, Dussor GO, Jeske NA, Patwardhan AM, Diogenes A, Trott AA, Hargreaves KM, Flores CM. Treatment of trigeminal ganglion neurons in vitro with NGF, GDNF or BDNF: effects on neuronal survival, neurochemical properties and TRPV1-mediated neuropeptide secretion. BMC Neurosci 2005, 6:4. 10.1186/1471-2202-6-4, 548274, 15667652.
42. Mezey E, Toth ZE, Cortright DN, Arzubi MK, Krause JE, Elde R, Guo A, Blumberg PM, Szallasi A. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci USA 2000, 97:3655-3660. 10.1073/pnas.060496197, 10725386.
43. Guo A, Vulchanova L, Wang J, Li X, Elde R. Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur J Neurosci 1999, 11:946-958. 10.1046/j.1460-9568.1999.00503.x, 10103088.
44. Valtschanoff JG, Rustioni A, Guo A, Hwang SJ. Vanilloid receptor VR1 is both presynaptic and postsynaptic in the superficial laminae of the rat dorsal horn. J Comp Neurol 2001, 436:225-235. 10.1002/cne.1063, 11438926.
45. Hwang SJ, Valtschanoff JG. Vanilloid receptor VR1-positive afferents are distributed differently at different levels of the rat lumbar spinal cord. Neurosci Lett 2003, 349:41-44. 10.1016/S0304-3940(03)00750-X, 12946582.
46. Doly S, Fischer J, Salio C, Conrath M. The vanilloid receptor-1 is expressed in rat spinal dorsal horn astrocytes. Neurosci Lett 2004, 357:123-126. 10.1016/j.neulet.2003.12.051, 15036590.
47. Ueda M, Kuraishi Y, Sugimoto K, Satoh M. Evidence that glutamate is released from capsaicin-sensitive primary afferent fibers in rats: study with on-line continuous monitoring of glutamate. Neurosci Res 1994, 20:231-7. 10.1016/0168-0102(94)90092-2, 7530819.
48. Zhou Y, Zhou ZS, Zhao ZQ. PKC regulates capsaicin-induced currents of dorsal root ganglion neurons in rats. Neuropharmacology 2001, 41:601-608. 10.1016/S0028-3908(01)00106-X, 11587715.
49. Ferrini F, Salio C, Vergnano AM, Merighi A. Vanilloid receptor-1 (TRPV1)-dependent activation of inhibitory neurotransmission in spinal substantia gelatinosa neurons of mouse. Pain 2007, 129:195-209. 10.1016/j.pain.2007.01.009, 17317009.
50. Zhou HY, Zhang HM, Chen SR, Pan HL. Increased C-fiber nociceptive input potentiates inhibitory glycinergic transmission in the spinal dorsal horn. J Pharmacol Exp Ther 2008, 324:1000-1010. 10.1124/jpet.107.133470, 18079355.
51. Chuang HH, Prescott ED, Kong H, Shields S, Jordt SE, Basbaum AI, Chao MV, Julius D. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature 2001, 411:957-962. 10.1038/35082088, 11418861.
52. Tominaga M, Wada M, Masu M. Potentiation of capsaicin receptor activity by metabotropic ATP receptors as a possible mechanism for ATP-evoked pain and hyperalgesia. Proc Natl Acad Sci USA 2001, 98:6951-6956. 10.1073/pnas.111025298, 34459, 11371611.
53. Moriyama T, Iida T, Kobayashi K, Higashi T, Fukuoka T, Tsumura H, Leon C, Suzuki N, Inoue K, Gachet C, Noguchi K, Tominaga M. Possible involvement of P2Y2 metabotropic receptors in ATP-induced transient receptor potential vanilloid receptor 1-mediated thermal hypersensitivity. J Neurosci 2003, 23:6058-6062.
54. Zhang N, Inan S, Cowan A, Sun R, Wang JM, Rogers TJ, Caterina M, Oppenheim JJ. A proinflammatory chemokine, CCL3, sensitizes the heat- and capsaicin-gated ion channel TRPV1. Proc Natl Acad Sci USA 2005, 102:4536-4541. 10.1073/pnas.0406030102, 555471, 15764707.
55. Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, Koltzenburg M, Basbaum AI, Julius D. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000, 288:306-313. 10.1126/science.288.5464.306, 10764638.
56. Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, Harries MH, Latcham J, Clapham C, Atkinson K, Hughes SA, Rance K, Grau E, Harper AJ, Pugh PL, Rogers DC, Bingham S, Randall A, Sheardown SA. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000, 405:183-187. 10.1038/35012076, 10821274.
57. Lukacs V, Thyagarajan B, Balla A, Varnai P, Balla T, Rohacs T. Dual regulation of TRPV1 by phosphoinositides. J Neurosci 2007, 27:7070-7080. 10.1523/JNEUROSCI.1866-07.2007, 17596456.
58. Vetter I, Wyse BD, Roberts-Thomson SJ, Monteith GR, Cabot PJ. Mechanisms involved in potentiation of transient receptor potential vanilloid 1 responses by ethanol. Eur J Pain 2008, 12:441-54. 10.1016/j.ejpain.2007.07.001, 17826200.
59. Stein AT, Ufret-Vincenty CA, Hua L, Santana LF, Gordon S. Phosphoinositide 3-Kinase Binds to TRPV1 and Mediates NGF-stimulated TRPV1 Trafficking to the Plasma Membrane. J Gen Physiol 2006, 128:509-522. 10.1085/jgp.200609576, 2151588, 17074976.
60. Pitchford S, Levine JD. Prostaglandins sensitize nociceptors in cell culture. Neurosci Lett 1991, 132:105-8. 10.1016/0304-3940(91)90444-X, 1724065.
61. Moriyama T, Higashi T, Togashi K, Iida T, Segi E, Sugimoto Y, Tominaga T, Narumiya S, Tominaga M. Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol Pain 2005, 1:3. 10.1186/1744-8069-1-3, 1074353, 15813989.
62. Bhave G, Zhu W, Wang H, Brasier DJ, Oxford GS, Gereau RW. cAMP-dependent protein kinase regulates desensitization of the capsaicin receptor (VR1) by direct phosphorylation. Neuron 2002, 35:721-731. 10.1016/S0896-6273(02)00802-4, 12194871.
63. Rathee PK, Distler C, Obreja O, Neuhuber W, Wang GK, Wang SY, Nau C, Kress M. PKA/AKAP/VR-1 module: A common link of Gs-mediated signaling to thermal hyperalgesia. J Neurosci 2002, 22:4740-4745.
64. Shin J, Cho H, Hwang SW, Jung J, Shin CY, Lee SY, Kim SH, Lee MG, Choi YH, Kim J, Haber NA, Reichling DB, Khasar S, Levine JD, Oh U. Bradykinin-12-lipoxygenase-VR1 signaling pathway for inflammatory hyperalgesia. Proc Natl Acad Sci USA 2002, 99:10150-10155. 10.1073/pnas.152002699, 126639, 12097645.
65. Hucho T, Levine JD. Signaling pathways in sensitization: toward a nociceptor cell biology. Neuron 2007, 55:365-76. 10.1016/j.neuron.2007.07.008, 17678851.
66. Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002, 36:57-68. 10.1016/S0896-6273(02)00908-X, 12367506.
67. Zhang X, Huang J, McNaughton PA. NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J 2005, 24:4211-23. 10.1038/sj.emboj.7600893, 1356334, 16319926.
68. Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron 2006, 52:77-92. 10.1016/j.neuron.2006.09.021, 1810425, 17015228.
69. Winston J, Toma H, Shenoy M, Pasricha PJ. Nerve growth factor regulates VR-1 mRNA levels in cultures of adult dorsal root ganglion neurons. Pain 2001, 89:181-6. 10.1016/S0304-3959(00)00370-5, 11166474.
70. Hudson LJ, Bevan S, Wotherspoon G, Gentry C, Fox A, Winter J. VR1 protein expression increases in undamaged DRG neurons after partial nerve injury. Eur J Neurosci 2001, 13:2105-14. 10.1046/j.0953-816x.2001.01591.x, 11422451.
71. Lappin SC, Randall AD, Gunthorpe MJ, Morisset V. TRPV1 antagonist, SB-366791, inhibits glutamatergic synaptic transmission in rat spinal dorsal horn following peripheral inflammation. Eur J Pharmacol 2006, 540:73-81. 10.1016/j.ejphar.2006.04.046, 16737693.
72. Kanai Y, Nakazato E, Fujiuchi A, Hara T, Imai A. Involvement of an increased spinal TRPV1 sensitization through its up-regulation in mechanical allodynia of CCI rats. Neuropharmacology 2005, 49:977-84. 10.1016/j.neuropharm.2005.05.003, 15998524.
73. Vilceanu D, Honore P, Hogan QH, Stucky CL. Spinal nerve ligation in mouse upregulates TRPV1 heat function in injured IB4-positive nociceptors. J Pain 2010, 11:88-99.
74. Watson CP, Evans RJ, Watt VR. Post-herpetic neuralgia and topical capsaicin. Pain 1988, 33:333-40. 10.1016/0304-3959(88)90292-8, 2458561.
75. Ellison N, Loprinzi CL, Kugler J, Hatfield AK, Miser A, Sloan JA, Wender DB, Rowland KM, Molina R, Cascino TL, Vukov AM, Dhaliwal HS, Ghosh C. Phase III placebo-controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients. J Clin Oncol 1997, 15:2974-2980.
76. Low PA, Opfer-Gehrking TL, Dyck PJ, Litchy WJ, O'Brien PC. Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy. Pain 1995, 62:163-8. 10.1016/0304-3959(94)00261-C, 8545141.
77. Rashid MH, Inoue M, Bakoshi S, Ueda H. Increased expression of vanilloid receptor 1 on myelinated primary afferent neurons contributes to the antihyperalgesic effect of capsaicin cream in diabetic neuropathic pain in mice. J Pharmacol Exp Ther 2003, 306:709-717. 10.1124/jpet.103.050948, 12724350.
78. Simone DA, Ngeow JY, Putterman GJ, LaMotte RH. Hyperalgesia to heat after intradermal injection of capsaicin. Brain Res 1987, 418:201-213. 10.1016/0006-8993(87)90982-6, 3664271.
79. Gilchrist HD, Allard BL, Simone DA. Enhanced withdrawal responses to heat and mechanical stimuli following intraplantar injection of capsaicin in rats. Pain 1996, 67:179-188. 10.1016/0304-3959(96)03104-1, 8895246.
80. Perkins MN, Campbell EA. Capsazepine reversal of the antinociceptive action of capsaicin in vivo. Br J Pharmacol 1992, 107:329-33. 1907885, 1422585.
81. McIntyre P, McLatchie LM, Chambers A, Phillips E, Clarke M, Savidge J, Toms C, Peacock M, Shah K, Winter J, Weerasakera N, Webb M, Rang HP, Bevan S, James IF. Pharmacological differences between the human and rat vanilloid receptor 1 (VR1). Br J Pharmacol 2001, 132:1084-1094. 10.1038/sj.bjp.0703918, 1572656, 11226139.
82. Savidge J, Davis C, Shah K, Colley S, Phillips E, Ranasinghe S, Winter J, Kotsonis P, Rang H, McIntyre P. Cloning and functional characterization of the guinea pig vanilloid receptor 1. Neuropharmacology 2002, 43:450-456. 10.1016/S0028-3908(02)00122-3, 12243775.
83. Walker KM, Urban L, Medhurst SJ, Patel S, Panesar M, Fox AJ, McIntyre P. The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 2003, 304:56-62. 10.1124/jpet.102.042010, 12490575.
84. Valenzano KJ, Grant ER, Wu G, Hachicha M, Schmid L, Tafesse L, Sun Q, Rotshteyn Y, Francis J, Limberis J, Malik S, Whittemore ER, Hodges D. N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties. J Pharmacol Exp Ther 2003, 306:377-386. 10.1124/jpet.102.045674, 12721338.
85. Pomonis JD, Harrison JE, Mark L, Bristol DR, Valenzano KJ, Walker K. N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 2003, 306:387-93. 10.1124/jpet.102.046268, 12721336.
86. Honore P, Wismer CT, Mikusa J, Zhu CZ, Zhong C, Gauvin DM, Gomtsyan A, El Kouhen R, Lee CH, Marsh K, Sullivan JP, Faltynek CR, Jarvis MF. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J Pharmacol Exp Ther 2005, 314:410-21. 10.1124/jpet.105.083915, 15837818.
87. Gavva NR, Tamir R, Qu Y, Klionsky L, Zhang TJ, Immke D, Wang J, Zhu D, Vanderah TW, Porreca F, Doherty EM, Norman MH, Wild KD, Bannon AW, Louis JC, Treanor JJ. AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 2005, 313:474-84. 10.1124/jpet.104.079855, 15615864.
88. Cui M, Honore P, Zhong C, Gauvin D, Mikusa J, Hernandez G, Chandran P, Gomtsyan A, Brown B, Bayburt EK, Marsh K, Bianchi B, McDonald H, Niforatos W, Neelands TR, Moreland RB, Decker MW, Lee CH, Sullivan JP, Faltynek CR. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. J Neurosci 2006, 26:9385-93. 10.1523/JNEUROSCI.1246-06.2006, 16971522.
89. Bak A, Gore A, Yanez E, Stanton M, Tufekcic S, Syed R, Akrami A, Rose M, Surpaneni S, Bostick T, King A, Neervannan S, Ostovic D, Koparkar A. The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid cocrystal characterization and pharmacokinetics. J Pharm Sci 2008, 97:3942-56. 10.1002/jps.21280, 18214948.
90. Gavva NR, Treanor JJ, Garami A, Fang L, Surapaneni S, Akrami A, Alvarez F, Bak A, Darling M, Gore A, Jang GR, Kesslak JP, Ni L, Norman MH, Palluconi G, Rose MJ, Salfi M, Tan E, Romanovsky AA, Banfield C, Davar G. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 2008, 136:202-210. 10.1016/j.pain.2008.01.024, 18337008.
91. Gavva NR. Body-temperature maintenance as the predominant function of the vanilloid receptor TRPV1. Trends Pharmacol Sci 2008, 29:550-7. 10.1016/j.tips.2008.08.003, 18805596.
92. Steiner AA, Turek VF, Almeida MC, Burmeister JJ, Oliveira DL, Roberts JL, Bannon AW, Norman MH, Louis JC, Treanor JJ, Gavva NR, Romanovsky AA. Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors. J Neurosci 2007, 27:7459-68. 10.1523/JNEUROSCI.1483-07.2007, 17626206.
93. Gavva NR, Bannon AW, Hovland DN, Lehto SG, Klionsky L, Surapeneni S, Immke DC, Henley C, Arik L, Bak A, Davis J, Ernst N, Hever G, Kuang R, Shi L, Tamir R, Wang J, Wang W, Zajic G, Zhu D, Norman MH, Louis JC, Magal E, Treanor JJ. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. J Pharmacol Exp Ther 2007, 323:128-37. 10.1124/jpet.107.125674, 17652633.
94. Honore P, Chandran P, Hernandez G, Gauvin DM, Mikusa JP, Zhong C, Joshi SK, Ghilardi JR, Sevcik MA, Fryer RM, Segreti JA, Banfor PN, Marsh K, Neelands T, Bayburt E, Daanen JF, Gomtsyan A, Lee CH, Kort ME, Reilly RM, Surowy CS, Kym PR, Mantyh PW, Sullivan JP, Jarvis MF, Faltynek CR. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia. Pain 2009, 142:27-35. 10.1016/j.pain.2008.11.004, 19135797.
95. Lehto SG, Tamir R, Deng H, Klionsky L, Kuang R, Le A, Lee D, Louis JC, Magal E, Manning BH, Rubino J, Surapaneni S, Tamayo N, Wang T, Wang J, Wang J, Wang W, Youngblood B, Zhang M, Zhu D, Norman MH, Gavva NR. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats. J Pharmacol Exp Ther 2008, 326:218-29. 10.1124/jpet.107.132233, 18420600.
96. Rodella LF, Borsani E, Rezzani R, Ricci F, Buffoli B, Bianchi R. AM404, an inhibitor of anandamide reuptake decreases Fos-immunoreactivity in the spinal cord of neuropathic rats after non-noxious stimulation. Eur J Pharmacol 2005, 508:139-46. 10.1016/j.ejphar.2004.12.031, 15680264.
97. Costa B, Giagnoni G, Franke C, Trovato AE, Colleoni M. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol 2004, 143:247-50. 10.1038/sj.bjp.0705920, 1575333, 15313881.
98. Jhaveri MD, Richardson D, Chapman V. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol 2007, 152:624-32. 10.1038/sj.bjp.0707433, 2190014, 17704819.
99. Maione S, De Petrocellis L, de Novellis V, Moriello AS, Petrosino S, Palazzo E, Rossi FS, Woodward DF, Di Marzo V. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 2007, 150:766-81. 10.1038/sj.bjp.0707145, 2013858, 17279090.
100. Olah Z, Szabo T, Karai L, Hough C, Fields RD, Caudle RM, Blumberg PM, Iadarola MJ. Ligand-induced dynamic membrane changes and cell deletion conferred by vanilloid receptor 1. J Biol Chem 2001, 276:11021-30. 10.1074/jbc.M008392200, 11124944.
101. Karai L, Brown DC, Mannes AJ, Connelly ST, Brown J, Gandal M, Wellisch OM, Neubert JK, Olah Z, Iadarola MJ. Deletion of vanilloid receptor 1-expressing primary afferent neurons for pain control. J Clin Invest 2004, 113:1344-52. 398431, 15124026.
102. Neubert JK, King C, Malphurs W, Wong F, Weaver JP, Jenkins AC, Rossi HL, Caudle RM. Characterization of mouse orofacial pain and the effects of lesioning TRPV1-expressing neurons on operant behavior. Mol Pain 2008, 4:3-13. 10.1186/1744-8069-4-3, 2242785, 18199335.
103. Tender GC, Li YY, Cui JG. Vanilloid receptor 1-positive neurons mediate thermal hyperalgesia and tactile allodynia. Spine J 2008, 8:351-358. 10.1016/j.spinee.2007.08.005, 18029293.
104. Mezey E, Tóth ZE, Cortright DN, Arzubi MK, Krause JE, Elde R, Guo A, Blumberg PM, Szallasi A. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci USA 2000, 97:3655-3660. 10.1073/pnas.060496197, 16295, 10725386.
105. Roberts JC, Davis JB, Benham CD. [3H]Resiniferatoxin autoradiography in the CNS of wild-type and TRPV1 null mice defines TRPV1 (VR-1) protein distribution. Brain Res 2004, 995:176-183. 10.1016/j.brainres.2003.10.001, 14672807.
106. Szabo T, Biro T, Gonzalez AF, Palkovits M, Blumberg PM. Pharmacological characterization of vanilloid receptor located in the brain. Brain Res Mol Brain Res 2002, 98:51-57. 10.1016/S0169-328X(01)00313-8, 11834295.
107. Millan MJ. The induction of pain: an integrative review. Prog Neurobiol 1999, 57:1-164. 10.1016/S0301-0082(98)00048-3, 9987804.
108. Millan MJ. Descending control of pain. Prog Neurobiol 2002, 66:355-474. 10.1016/S0301-0082(02)00009-6, 12034378.
109. Liapi A, Wood JN. Extensive co-localization and heteromultimer formation of the vanilloid receptor-like protein TRPV2 and the capsaicin receptor TRPV1 in the adult rat cerebral cortex. Eur J Neurosci 2005, 22:825-834. 10.1111/j.1460-9568.2005.04270.x, 16115206.
110. Sasamura T, Sasaki M, Tohda C, Kuraishi Y. Existence of capsaicin-sensitive glutamatergic terminals in rat hypothalamus. Neuroreport 1998, 22:2045-2048.
111. Bodnar RJ, Kirchgessner A, Nilaver G, Mulhern J, Zimmerman EA. Intraventricular capsaicin: alterations in analgesic responsivity without depletion of substance P. Neuroscience 1982, 7:631-638. 10.1016/0306-4522(82)90068-9, 6175920.
112. Bodnar RJ, Simone DA, Kordower JH, Kirchgessner AL, Nilaver G. Capsaicin treatment and stress-induced analgesia. Pharmacol Biochem Behav 1983, 18:65-71. 10.1016/0091-3057(83)90253-8, 6681908.
113. Santos AR, Calixto JB. Ruthenium red and capsazepine antinociceptive effect in formalin and capsaicin models of pain in mice. Neurosci Lett 1997, 235:73-76. 10.1016/S0304-3940(97)00722-2, 9389599.
114. Hajós M, Engberg G, Elam M. Reduced responsiveness of locus coeruleus neurons to cutaneous thermal stimuli in capsaicin-treated rats. Neurosci Lett 1986, 70:382-387. 10.1016/0304-3940(86)90584-7, 3022199.
115. Hajós M, Jancsó G, Engberg G. Capsaicin-induced excitation of locus coeruleus neurons. Acta Physiol Scand 1987, 129:415-420. 10.1111/j.1748-1716.1987.tb08086.x, 3577824.
116. Marinelli S, Pascucci T, Bernardi G, Puglisi-Allegra S, Mercuri NB. Activation of TRPV1 in the VTA excites dopaminergic neurons and increases chemical- and noxious-induced dopamine release in the nucleus accumbens. Neuropsychopharmacology 2005, 30:864-870. 10.1038/sj.npp.1300615, 15562294.
117. Marinelli S, Vaughan CW, Christie MJ, Connor M. Capsaicin activation of glutamatergic synaptic transmission in the rat locus coeruleus in vitro. J Physiol 2002, 543:531-540. 10.1113/jphysiol.2002.022863, 2290516, 12205187.
118. Sasamura T, Kuraishi Y. Peripheral and central actions of capsaicin and VR1 receptor. Jpn J Pharmacol 1999, 80:275-280. 10.1254/jjp.80.275, 10496326.
119. Toldi J, Joo F, Wolfe JR. Capsaicin differentially influences somatosensory cortical responses evoked by peripheral electrical or mechanical stimulation. Neuroscience 1992, 49:135-139. 10.1016/0306-4522(92)90081-C, 1407542.
120. Calejesan AA, Kim SJ, Zhuo M. Descending facilitatory modulation of a behavioral nociceptive response by stimulation in the adult rat anterior cingulate cortex. Eur J Pain 2000, 4:83-96. 10.1053/eujp.1999.0158, 10833558.
121. Tang J, Ko S, Ding HK, Qiu CS, Calejesan AA, Zhuo M. Pavlovian fear memory induced by activation in the anterior cingulated cortex. Mol Pain 2005, 1:6. 10.1186/1744-8069-1-6, 1074356, 15813993.
122. Steenland HW, Ko SW, Wu LJ, Zhuo M. Hot receptors in the brain. Mol Pain 2006, 2:34-42. 10.1186/1744-8069-2-34, 1647269, 17092351.
123. Palazzo E, de Novellis V, Marabese I, Cuomo D, Rossi F, Berrino L, Rossi F, Maione S. Interaction between vanilloid and glutamate receptors in the central modulation of nociception. Eur J Pharmacol. 2002, 439:69-75.
124. McGaraughty S, Chu KL, Bitner RS, Martino B, El Kouhen R, Han P, Nikkel AL, Burgard EC, Faltynek CR, Jarvis M. Capsaicin infused into the PAG affects rat tail flick responses to noxious heat and alters neuronal firing in the RVM. J Neurophysiol 2003, 90:2702-2710. 10.1152/jn.00433.2003, 12815018.
125. Maione S, Bisogno T, de Novellis V, Palazzo E, Cristino L, Valenti M, Petrosino S, Guglielmotti V, Rossi F, Di Marzo V. Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther 2006, 316:969-982. 10.1124/jpet.105.093286, 16284279.
126. de Novellis V, Palazzo E, Rossi F, De Petrocellis L, Petrosino S, Guida F, Luongo L, Migliozzi A, Cristino L, Marabese I, Starowicz K, Di Marzo V, Maione S. The analgesic effect of N-arachidonoyl-serotonin, a FAAH inhibitor and TRPV1 receptor antagonist, associated with changes in rostral ventromedial medulla and locus coeruleus cell activity in rats. Neuropharmacology 2008, 55:1105-1113. 10.1016/j.neuropharm.2008.06.023, 18616956.
127. Starowicz K, Maione S, Cristino L, Palazzo E, Marabese I, Rossi F, de Novellis V, Di Marzo V. Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. J Neurosci 2007, 27:13739-13749. 10.1523/JNEUROSCI.3258-07.2007, 18077685.
128. Palazzo E, Rossi F, Maione S. Role of TRPV1 receptors in descending modulation of pain. Mol Cell Endocrinol 2008, 286:S79-83. 10.1016/j.mce.2008.01.013, 18325659.
129. Watkins LR, Milligan ED, Maier SF. Spinal cord glia: new players in pain. Pain 2001, 93:201-5. 10.1016/S0304-3959(01)00359-1, 11514078.
130. Luongo L, Palazzo E, Tambaro S, Giordano C, Gatta L, Scafuro MA, Rossi FS, Lazzari P, Pani L, de Novellis V, Malcangio M, Maione S. 1-(2',4'-dichlorophenyl)-6- methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3- carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice. Neurobiol Dis 2010, 37:177-85. 10.1016/j.nbd.2009.09.021, 19804829.
131. Carrier EJ, Kearn CS, Barkmeier AJ, Breese NM, Yang W, Nithipatikom K, Pfister SL, Campbell WB, Hillard CJ. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol. 2004, 65:999-1007.
132. Luongo L, Palazzo E, de Novellis V, Maione S. Role of endocannabinoid system in neuron-glia cross-talk. The Open Pain Journal 2010, 3:29-36.
133. Kim SR, Kim SU, Oh U, Jin BK. Transient receptor potential vanilloid subtype 1 mediates microglial cell death in vivo and in vitro via Ca2+-mediated mitochondrial damage and cytochrome c release. J Immunol 2006, 177:4322-9.
134. Amantini C, Mosca M, Nabissi M, Lucciarini R, Caprodossi S, Arcella A, Giangaspero F, Santoni G. Capsaicin-induced apoptosis of glioma cells is mediated by TRPV1 vanilloid receptor and requires p38 MAPK activation. J Neurochem 2007, 102:977-90. 10.1111/j.1471-4159.2007.04582.x, 17442041.
135. Chen Y, Willcockson HH, Valtschanoff JG. Influence of the vanilloid receptor TRPV1 on the activation of spinal cord glia in mouse models of pain. Exp Neurol 2009, 220:383-90. 10.1016/j.expneurol.2009.09.030, 19815011.